Mantle cell lymphoma in relapse: the role of emerging new drugs.
OBJECTIVE
Despite current advances in the therapy for newly diagnosed mantle cell lymphoma (MCL), relapsed MCL continues to have a poor prognosis. Advances in our understanding of the molecular pathogenesis of MCL are yielding many promising novel therapies.


RESULTS
This article reviews the unique biology of MCL and describes how our understanding of its cell cycle dysregulation, and impaired apoptotic pathways is yielding many potential therapeutic targets including cyclin D1 and the cell cycle regulatory proteins, inhibitors of mammalian target of rapamycin, the proteasome, and proapoptotic family members. Recent preclinical and clinical data with cdk inhibitors, histone deacetylase inhibitors, the proteasome inhibitor bortezomib, mammalian target of rapamycin inhibitors, and other experimental strategies such as immunotherapy and microRNA are discussed.


CONCLUSIONS
Understanding these targeted therapies in the context of the biology of MCL, has the potential to develop novel therapeutic platforms for the treatment of relapsed MCL, and will hopefully change the outcome for patients with this challenging clinical condition.
Diefenbach
Catherine S M
CS
New York University Cancer Institute, NYU Langone Medical Center, New York, NY, USA.
O'Connor
Owen A
OA
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor